loading

Recent events

GLuna Shrimp owner Gabriel Luna

AdvertisementX
AdvertisementX

R&D

Hofseth details promising drugs leads as losses go on

The Norwegian biotech firm saw losses continue in Q3, but noted multiple developments in the field of processing salmon offcuts for pharmaceuticals

By Undercurrent News | Nov. 5, 2021 10:20 GMT
Hofseth Biocare
Related

New customers up Hofseth BioCare’s sales, but losses continue

Institutional investors account for more than a third of 2020 seafood deals

Bumble Bee tuna

Hofseth BioCare sees improved Q4 performance despite loss-making year

Hofseth Biocare

Hofseth BioCare establishes Swiss subsidiary, appoints CEO

free read US wholesale: Week 2 seafood price assessments live

US wholesale: Week 2 seafood price assessments live

Grieg assures pause on Canadian salmon hatchery project is temporary

AdvertisementX

Norwegian biotech firm Hofseth Biocare (HBC) posted another quarter of losses in Q3, but detailed multiple promising new drugs leads and announced an investment from sustainable aquaculture fund Aqua-Spark.  [...]

Want to keep reading?

Sign up for a trial to have access to our articles!

Vannamei shrimp prices in East Java lead Indonesia’s upward trend in week 2

free read Canadian fisherman penalized for catching undersized lobsters

Research: Alaska red king crab populations genetically distinct

Ecuador’s AquaGold signs exclusive shrimp supply deal with China’s Guolian

AdvertisementX

Stay on the pulse

Get recommendations, data, editor’s picks, and the latest news from around the seafood world straight to your inbox.

Select your interests

Please select at least one newsletter d indicates our daily newsletters | 2w indicates twice-weekly | All others sent weekly All briefings are sent weekly, unless otherwise indicated
Region
Breaking news
Jobs
Species
Topic

Fill in your details

Please select at least one newsletter!
  • (eg new industry reports, prices data)
  • (eg subscription or report early birds)
  • (eg advertising, trade shows news)
How we handle your data We never share, sell or distribute our subscribers’ data. You may at any time unsubsribe from our newsletters, and request that we erase all information stored about you. Please check our Privacy policy for more details.

We use MailChimp and HubSpot as our email campaign platforms. By subscribing, you agree that the information you provide will be transferred to MailChimp and HubSpot for processing in accordance with their privacy policies (MailChimp privacy policy, HubSpot privacy policy) and terms (MailChimp terms, HubSpot terms).

Thank you. Please check your inbox to confirm your selection and start receiving newsletters.

Cookies on Undercurrent News

We use cookies for performance, security and analytics. To stop seeing this banner click Accept, or select Manage cookies to set your preferences and privacy settings.